Tolerability of Omalizumab in Asthma as a Major Compliance Factor: 10-Year Follow Up

BACKGROUND: There is a lack of data related to real life, long-term safety, tolerability and compliance of omalizumab treatment in asthma patients beyond 6 years. AIM: Study aimed to assess safety, tolerability, compliance and all reasons for treatment discontinuation during 10 years on omalizumab....

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Ahmad, Mona, Nurkic, Jasmina, Maher, Ahmed, Arifhodzic, Nermina, Jusufovic, Edin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Republic of Macedonia 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236047/
https://www.ncbi.nlm.nih.gov/pubmed/30455759
http://dx.doi.org/10.3889/oamjms.2018.394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236047/
https://www.ncbi.nlm.nih.gov/pubmed/30455759
http://dx.doi.org/10.3889/oamjms.2018.394

Ejemplares similares